Global Systemic Psoriasis Therapeutics Market 2018-2022 - Rise in Cost of Systemic Psoriasis Therapy / Intro of Biologics / Gene Therapy for Psoriasis / Use of Combination Therapy - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Aug 30, 2018--The “Global Systemic Psoriasis Therapeutics Market 2018-2022” report has been added to ResearchAndMarkets.com’s offering.
The Global Systemic Psoriasis Therapeutics Market to grow at a CAGR of 10.07% during the period 2018-2022.
This report has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. To calculate the market size, the report considers the revenue generated from sale of different systemic psoriasis therapeutics.
One trend affecting this market is the rise in cost of systemic psoriasis therapy. The cost of the treatment depends on the severity of the disease. The first line of treatment is usually a systemic agent, and if ineffective a more potent systemic agent is used which increases the cost of treatment.
According to the report, one driver influencing this market is the need for affordable therapies. Topical treatments are most often purchased medication. Biologics are the most expensive medication and treatment failure can increase the medication cost.
Further, the report states that one challenge affecting this market is the patent expiry of drugs. The patent for major biologics for systemic psoriasis therapy have expired, which increases chances of adoption of biosimilars.
Key vendorsAbbVie Amgen Celgene Johnson & Johnson
Key Topics Covered:
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
PART 05: MARKET SIZING 2017-2022
PART 06: FIVE FORCES ANALYSISBargaining power of buyers Bargaining power of suppliers Threat of new entrants Threat of substitutes Threat of rivalry Market condition
PART 07: PIPELINE ANALYSISPipeline analysis Discontinued psoriasis therapies
PART 08: MARKET SEGMENTATION BY PRODUCTSegmentation by product Comparison by product Small molecules Biologics Market opportunity by product
PART 09: MARKET SEGMENTATION BY ROAOral Parenteral
PART 10: MARKET SEGMENTATION BY SEVERITY OF DISEASE
PART 11: MARKET SEGMENTATION BY END-USERSegmentation by end-user Hospitals Retail pharmacies
PART 12: CUSTOMER LANDSCAPE
PART 13: REGIONAL LANDSCAPEGeographical segmentation Regional comparison Market opportunity
PART 14: DECISION FRAMEWORK
PART 15: DRIVERS AND CHALLENGES
PART 16: MARKET TRENDSRise in cost of systemic psoriasis therapy Introduction of biologics Gene therapy for psoriasis Use of combination therapy Research in precision healthcare infrastructure
PART 17: VENDOR LANDSCAPEOverview Landscape disruption
PART 18: VENDOR ANALYSISVendors covered Vendor classification Market positioning of vendors
For more information about this report visit https://www.researchandmarkets.com/research/d66xbp/global_systemic?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180830005674/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Psoriasis Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 08/30/2018 12:49 PM/DISC: 08/30/2018 12:49 PM